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ABSTRACT 
 
The ionization constants (pKa) and the pH-dependent solubility (log S-pH) of six phenothiazine 
derivatives (promazine hydrochloride, chlorpromazine hydrochloride, triflupromazine 
hydrochloride, fluphenazine dihydrochloride, perphenazine free base, and trifluoperazine 
dihydrochloride) were determined at 25 and 37 oC.  The pKa values of these low-soluble 
surface active molecules were determined by the cosolvent method (n-propanol/water at 37 oC 
and methanol/water at 25 oC).  The log S-pH profiles were measured at 24 h incubation time in 
0.15 M phosphate buffers.  The log S-pH “shape-template” method, which critically depends on 
accurate pKa values (determined independently of solubility data), was used to propose 
speciation models, which were subsequently refined by rigorous mass-action weighted 
regression procedure described recently.  Differential scanning calorimetry (DSC), UV-visible 
spectrophotometry, potentiometric, and high performance liquid chromatography (HPLC) 
measurements were used to characterize the compounds.  The intrinsic solubility (S0) values of 
the three least-soluble drugs (chlorpromazine·HCl, triflupromazine·HCl, and 
trifluoperazine·2HCl) at 25 oC were 0.5, 1.1, and 2.7 μg/mL (resp.).  These values increased to 
5.5, 9.2, and 8.7 μg/mL (resp.) at the physiological temperature.  The enthalpies of solution for 
the latter compounds were exceptionally high positive (endothermic) values (99-152 kJ·mol-1).  
Cationic sub-micellar aggregates were evident (from the distortions in the log S-pH profiles) for 
chlorpromazine, fluphenazine, perphenazine, and trifluoperazine at 25 oC. The effects persisted 
at 37 oC for chlorpromazine and trifluoperazine.  The solids in suspension were apparently 
amorphous in cases where the drugs were introduced as the chloride salts. 
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1.  Introduction 
 
Many surface-active ionizable drug molecules, especially those which are poorly soluble, 
exhibit complicated aqueous solution chemistry, in some ways like that of common detergents 
and bile salt surfactants.  Dilute aqueous solutions of detergents (e.g., sodium dodecyl sulfate) 
consist of monomers located at the air-water interface.  When the amount of the surfactant is 
increased past the critical micelle concentration (CMC), the monomer concentration becomes 
constant (at the CMC), as large water-soluble micelles (aggregation numbers ~50, low 
polydispersity) form, accompanied by sharp transitions in many physical properties of the 
solution (Pramauro and Pelezetti, 1996, Ekwall, 1954; Fontell, 1971; Mukerjee and Cardinal, 
1976; Chang and Cardinal, 1978).  
Unlike that of the well-studied surfactants, the solution chemistry of low-soluble 
amphiphilic ionizable drugs is often associated with the formation of sub-micellar aggregates, 
with examples such as amiodarone (pentamer, pH < 7), hydralazine (hexamer, pH < 7), 
pramoxine (octamer, pH < 8) (Bouligand et al., 1998; Bergström et al., 2004), and 
prostaglandin F2α  (octamer, pH > 5) (Roseman and Yalkowsky, 1973).  There are only a 
handful of other examples of sub-micellar aggregation (Higuchi et al., 1953; Bogardus and 
Blackwood, 1979; Serajuddin and Rosoff, 1984; Serajuddin and Jarowski, 1985; Fini et al., 
1995; Zhu and Streng, 1996; Ledwidge and Corrigan, 1998; Jinno et al., 2000).  In the above 
examples, the stoichiometries of aggregation were estimated from the re-analysis of published 
solubility-pH data (Avdeef 2007, 2012; Völgyi et al., 2013; Avdeef, 2014a,b; Butcher et al., 
2015).   
The above drugs precipitate over a wide range of pH, forming solid phases in contact 
with dissolved monomers, and often, also with water-soluble sub-micellar aggregates (e.g., 
dimers, trimers …), and in some cases, fully-formed micelles.   Such aggregates are expected 
to have high solubility, strongly depend on temperature.  Their solution behavior is poorly 
characterized and incompletely understood.  
More recently, independent techniques have suggested the presence of sub-micellar 
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aggregates: Caco-2 permeability-pH data have been used to propose the presence of 
aggregated retinoic acid (Avdeef and Tam, 2010); ESI-Q-TOF-MS/MS was used to confirm the 
presence of dimers and trimers of cefadroxil in solution Shoghi et al. (2012).   
Surface-active phenothiazines are prone to micelle formation.  Attwood et al. (1974) 
found that distilled water solutions of promazine hydrochloride and chlorpromazine 
hydrochloride at 34 oC form small micelles, in aggregated units of eleven monomers, 
possessing eight units of net positive charge.  Zografi and Zarenda (1966) noted that a 2-5 μM 
(below solubility limit) alkaline solution (pH 9-12) prepared from chlorpromazine free base 
showed no surface activity.  However, 30 μM chlorpromazine hydrochloride at pH 9 produced 
stable supersaturated solutions, which partly separated as oil (liquid-liquid phase separation, 
LLPS) which was more soluble than the crystalline free base.   
The aim of the present study was to characterize aqueous solubility-pH behavior  
of several poorly-soluble CNS-acting phenothiazine derivatives, including promazine·HCl, 
chlorpromazine·HCl, triflupromazine·HCl, fluphenazine·2HCl, perphenazine (free base), and 
trifluoperazine·2HCl.  The phenothiazines belong to the neuroleptics class of drugs. They 
potently block dopamine receptors, and have been used for many years to treat the clinical 
symptoms of psychosis. Phenothiazines may also weakly interact with receptors 5-HT2, 
effecting their antipsychotic activity. The substances can also inhibit neuroleptic receptors: 
histamine H1, which is associated with sedation, and muscarinic M1, which is responsible for 
symptoms such as memory impairment, drowsiness, and the antiemetic response (Patrick, 
1995; Jaszczyszyn et al., 2012).  
Phenothiazine solubility was measured after 24 h in 0.15 M phosphate buffers in the pH 
interval from 6 to 11.  The intent was to characterize the uncharged-drug precipitate region.  
However, some of the data revealed the presence of drug-phosphate salt precipitates in neutral 
solution.  The ionization constants (pKa), which are required for the interpretation of the 
solubility profiles, were measured by the cosolvent potentiometric and spectrophotometric 
methods.  Both measurements were performed at 25 and 37 oC.  Sub-micellar reactions were 
anticipated, given the surface activity of such compounds (Zografi et al., 1964; Zografi and 
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Zarenda, 1966; Sorby et al., 1966; Green, 1967; Florence and Parfitt, 1971; Attwood et al., 
1974; Liu and Hurwitz, 1977; Attwood et al., 1997).  
 
2. Materials and methods 
 
2.1 Chemicals and reagents 
The phenothiazine drugs (Figure 1) were obtained from Sigma Aldrich: promazine 
hydrochloride (CAS Registry No. 53-60-1), chlorpromazine hydrochloride (CAS Registry No. 
69-09-0), triflupromazine hydrochloride (CAS Registry No. 1098-60-8), perphenazine free base  
(CAS Registry No. 58-39-9), fluphenazine dihydrochloride (CAS Registry No. 146-56-5), and 
trifluoperazine dihydrochloride (CAS Registry No. 440-14-5).  The powders or small crystals  
were used as received, without further purification. Other chemicals used were as follows: 
n-propanol (n-PrOH) for cosolvent titrations (CAS Registry No. 71-23-8, Panreac, 99.5%),  
methanol (MeOH) for HPLC – super gradient (CAS Registry No. 67-56-1, POCH, 99.9%), 
hydrochloric acid (CAS Registry No. 7647-01-0, POCH, 35-38%), sodium hydroxide (CAS 
Registry No. 1310-73-2, POCH, 98.8%), potassium dihydrogen phosphate (CAS Registry No. 
7778-77-0, POCH, 99.5%), dipotassium hydrogen phosphate (CAS Registry No. 7758-11-4, 
POCH, 99%), phosphoric acid (CAS Registry No. 7664-38-2, POCH, 85%), potassium 
hydroxide (CAS Registry No. 1310-58-3, POCH, 85%), disodium hydrogen phosphate (CAS 
Registry No. 7558-79-4, POCH, 99%), borax (CAS Registry No. 1303-96-4, POCH 99.5%), 
sodium chloride (CAS Registry No. 7647-14-5, POCH, 99.5%). Water was purified by the 
Milli-Q® plus system from Millipore (Billerica, MA, USA) with a resistivity of 18.2 MΩ·cm. 
 
2.2 pKa measurements  
Preliminary pKa values were determined at 25 oC by the traditional Bates-Schwarzenbach 
spectrophotometric method (Domańska et al., 2009).  However, some of the compounds 
proved to be difficult to characterize, since the method assumes that the Henderson-
Hasselbalch equation is valid and that the sample remains fully dissolved during the 
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measurement. 
Due to the very low solubility and surface activity of the phenothiazines, the pKa values 
were also measured using purpose-built automated pKa instruments, based on both 
potentiometric and spectrophotometric methods (Takács-Novák et al., 2001; Völgyi et al., 2007; 
Box et al., 2007; Sun and Avdeef, 2011).  Specifically, the pKa values of fluphenazine·2HCl, 
perphenazine and trifluoperazine·HCl were assayed at 37 oC and I = 0.15 M by the following 
methods: (a) spectrophotometric in aqueous solution (D-PAS UV instrument, Sirius Analytical, 
UK), (b) potentiometric in aqueous solution (GLpKa instrument, Sirius Analytical, UK), and  
(c) potentiometric using n-PrOH as cosolvent, where blank titrations were performed using  
the particular solvent composition used later on the pKa determination.  In the latter method, 
densities at different cosolvent compositions, needed to define weight percentage (wt%), were 
obtained from the literature (Wohlfarth, 2008). Two series from 15 to 33 wt% n-PrOH were 
performed in two consecutive weeks. 
At 37 oC, the use of methanol is not recommended, due to its high volatility; n-propanol 
is more suitable, having a vapor pressure comparable to that of water.   
The same approach was tried with promazine·HCl, chlorpromazine·HCl, and 
triflupromazine·HCl at 37ºC and I = 0.15 M.  However, not all methods worked, due to 
extensive precipitation in alkaline solutions. Triflupromazine·HCl was evaluated at 25 oC and 
I = 0.15 M in MeOH cosolvent systems: potentiometrically (GLpKa) in the interval 34-64 wt% 
MeOH, and spectrophotometrically (D-PAS) in 5-52 wt% MeOH. 
The pKa values at 25 oC for chlorpromazine·HCl, promazine·HCl, fluphenazine·2HCl, 
perphenazine, and trifluoperazine·2HCl were taken from literature sources, determined by 
extrapolation from alcohol/water media (Avdeef, 1994, 2001; Shalaeva et al., 2008; Tsinman 
et al., 2010).  
 
2.3 pH-Dependent solubility studies 
The shake flask method was used to determine the solubility at 25 and 37 oC. Each drug was 
added in excess to 10 mL of 0.15 M KH2PO4 or K2HPO4. The test tubes with the drug 
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suspensions were placed on a plate shaker. The solutions were thermostated ( 0.1 oC) using a 
circulating bath (Lauda A3, Germany).  The pH of each solution was measured (CPC-401 
ELMETRON, analysio GmbH, Germany, pH meter,  0.01 resolution), and adjusted as 
necessary, either with 0.1 M KOH or 0.1 M H3PO4, to the desired pH value. These values were 
re-checked at various times during the stirring. The experiment was completed when at least 
three pH measurements performed at an early, an intermediate and a late time-point of the 24 
h period resulted in the same pH value.  After 24 h, excess solid was separated using a 
rotating-bottle centrifuge at 5000 RPM for 20 min (Hettich Zenrifugen, EBA 20) or by filtration. 
The pH values were also measured of the supernatants, in order to verify that the drug 
solutions had the same pH value as the suspensions. The concentration of the drug in the 
supernatant solution was determined by an HPLC procedure with single-wavelength UV 
detection. All compounds were analysed in quadruplicate at each pH value. 
 
2.4 HPLC analysis 
Drug concentration in each sample was measured with HPLC-UV-vis apparatus, consisting of  
the 1200 Series Quat pump, vacuum degasser, and DAD/MWD (Agilent Technologies). A C18 
analytical column (4.6 mm × 150 mm) with a mean particle size of 5 μm was used.  Two 
solutions were used as a mobile phase: methanol (A) and phosphate buffer, pH = 7 (B). 
Injection volumes of 20 μL were used during the analysis.  The limit of detection (LOD) in the 
method used was <10 μM.  The chromatographic conditions for all the drugs are shown in 
Table 1. 
 
2.5 Refinement of Intrinsic, Salt Solubility and Aggregation Constants 
The solubility analysis, refinement, and simulation computer program, pDISOL-XTM 
(in-ADME Research), was used in this study.  The mathematical approach in pDISOL-X has 
been described by Völgyi et al. (2013), and the program has been applied in several other 
recent studies (Avdeef, 2014a, b; Butcher et al., 2015; Avdeef, 2015a).  Briefly, the novel data 
analysis method uses solubility as a function of pH, log S-pH, as measured input data from any 
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analytical technique (along with standard deviations, SD(log S)). The mass action algorithm 
considers the contribution of all species proposed to be present in solution, including all buffer 
components.  The approach does not assume the validity of the Henderson-Hasselbalch (HH) 
relationship, nor does it depend on any explicitly derived extensions of the HH equations. The 
mass action algorithm derives its own implicit equations internally, given any practical number 
of reactions and estimated constants, which are subsequently refined by weighted nonlinear 
least-squares regression (Avdeef, 2012; Völgyi et al., 2013). Therefore, in principal, drug-salt 
precipitates, -aggregates, -complexes, - bile salts, -surfactant can be evaluated.  The presence 
of specific buffer-drug species can be tested.  The program assumes an initial condition of a 
suspension of the solid drug in a solution, ideally with the suspension saturated over a wide 
range of pH.  The program calculates the distribution of species consequent to a sequence of 
additions of standardized strong-acid titrant HCl (or ionizable-acid titrants H3PO4, H2SO4, acetic 
acid, maleic acid, lactic acid) to simulate the suspension pH-speciation down to pH < 1, the 
staging point for the subsequent operation.  A sequence of perturbations with standardized 
strong-base titrant (e.g., NaOH) is simulated, and solubility calculated at each point (in pH 
steps of 0.005-0.2), until pH > 12 is reached.  The ionic strength, I, is rigorously calculated at 
each step, and pKa values (as well as solubility products, aggregation and complexation 
constants) are accordingly adjusted for changes in I from a benchmark level of 0.15 M (Avdeef, 
1992, 2012).   
At the end of the pH-speciation simulation, the calculated log S vs. pH curve is 
compared to measured log S vs. pH.  A user-supervised log S-weighted nonlinear least 
squares refinement commences to refine the user-proposed solution model, using internally-
derived analytical expressions for the differential equations. The process is repeated until the 
differences between calculated and measured log S values reach a minimum, as described 
elsewhere in detail. 
 
2.6 Thermodynamics measurements 
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 The temperature and enthalpy of fusion (Tfus,1 and fusH1) and the temperature and 
enthalpy of solid–solid phase transition (Ttr,1 and trH1) were measured for the starting forms of 
the solids using a differential scanning microcalorimetry technique at the 5 K · min-1 scan rate 
with the power sensitivity of 16 mJ · s-1 and with the recorder sensitivity of 5 mV. The Perkin-
Elmer Pyris 1 apparatus was calibrated with a 0.999999 mol fraction purity indium sample.   
 In addition, solids were separated from the suspensions by filtration after 24 hours near 
pH 7 and 10, where they were expected to be in the free-base form.  The solids were rinsed and 
dried, after which DSC measurements were made. 
 
3. Results and discussion  
 
3.1 Ionic strength dependence of constants: pKa, aggregation, solubility products 
Table 2 indicates that some of the literature pKa values were determined by capillary 
electrophoresis at ionic strength, I = 0.05 M, whereas the rest of the pKa values were 
determined near I = 0.15 M.  This is not problematic, since pKa values of monoprotic bases are 
minimally affected by changes in the ionic strength in the 0.05 – 0.15 M range. 
 However, the same is not so for the other constants (e.g., 2-pKa bases, aggregation 
constants, solubility products). Ionic strength is not easily controlled in solubility-pH 
measurement, especially if the drug is introduced as a salt, or if highly-charged aggregates 
form, or if salts precipitate. Ionic strength can vary according to pH of the solution.  Also, the 
use of 0.15 M phosphate buffer contributes to the total ionic strength.  The ionic strength 
dependence of charged-species aggregation constants and solubility products can be 
substantial. In the current set of log S-pH measurements, the average ionic strength ranged 
from 0.32 to 0.36 M.  Had we specifically intended to study the phosphate salt formation, then 
large sample weight would have been needed (cf., Sec. 3.3.10).  To reach the point where 
phosphate salts of chlorpromazine, fluphenazine and trifluoperazine would have precipitated, 
the predicted ionic strength would have reached 1.6 M.   
 The pDISOL-X program is designed to make appropriate reconciliation for point-by-point 
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variation in ionic strength.  A reference value, Iref, is selected, typically set equal to the value of 
the mean ionic strength from the pKa determination (e.g., 0.15 M).  The constants in the 
solubility calculation are iteratively refined with respect to the fixed value of Iref, but are 
continuously adjusted in the mass balance calculation to the variable ionic strength, I, for each 
value of pH.  The procedure includes the calculation of the activity coefficients using hydration 
theory proposed by Stokes and Robinson (1948), and has been detailed elsewhere (Wang et 
al., 2002; Völgyi et al., 2013). 
 
3.2 pKa Determination 
The results of the pKa analysis are summarized in Table 2.  Figure 2 shows the weighted linear 
regression cosolvent plots of the phenothiazines at 25 and 37 oC.  
The measurement of the pKa of many of the phenothiazines proved to be quite 
challenging, especially at 25 oC.  It was found that the pKa values estimated by the Bates-
Schwarzenbach method were subject to systematic error, likely due to the formation of sub-
micellar aggregates and precipitation at high pH with several of the drugs.  For example, 
fluphenazine at 25 oC (Figure 3g) might appear to have a pKa = 8.73 (rather than 7.84), were it 
not recognized that aggregates form.  
The potentiometric pKa measurements in aqueous solution were particularly problematic 
for chlorpromazine·HCl, promazine·HCl and triflupromazine·HCl due to their low solubility, even 
at 37 oC. In very dilute solution, it was possible to determine the pKa of promazine·HCl 
spectrophotometrically. Some spectrophotometric titrations of chlorpromazine·HCl and 
triflupromazine·HCl had to be aborted because of precipitation at pH > 9.5. In those cases, final 
spectrophotometric pKa values were calculated as the mean value of results from all titrations 
(from complete and aborted titration curves, but only when the number of experimental points 
before precipitation was sufficient for the determination).  
The simultaneous determination of pKa1 and pKa2 of fluphenazine·2HCl, perphenazine, 
and trifluoperazine·2HCl from the whole titration data taken from single spectrophotometric 
experiments led to poor fittings for perphenazine and trifluoperazine·2HCl, but single pKa 
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fittings (pKa1 or pKa2 separately) allowed a successful determinations.  In the aqueous 
potentiometric determinations, only pKa1 was successfully determined, since the compounds 
precipitated at pH values close to pKa2. The potentiometric n-PrOH/water method was 
successful in determining both of the pKa values of the three piperazine derivatives at 37 oC. 
Triflupromazine·HCl at 25 oC and I = 0.15 M was first studied in 34-64 wt% MeOH. 
Below 40 wt%, there were signs of some precipitation at elevated pH. The long-reach 
extrapolated pKa was 9.58 ± 0.03, almost identical to that of chlorpromazine·HCl.  
Subsequently, the spectrophotometric study was conducted to confirm this value. It was 
possible to work with significantly lower concentrations, thus extending the cosolvent range 
considerably, to 5 - 52 wt% MeOH.  The extrapolated value was 9.49 ± 0.01.  It was decided to 
pool the data (37 individual titrations) into a single weighted linear regression analysis, which 
produced the final pKa 9.47 ± 0.01.  The linearity of the plot in Figure 2e over the large range of 
MeOH/water ratios makes this pKa value highly reliable. 
The 25 oC promazine·HCl MeOH/water-extrapolated pKa 9.62 ± 0.10 (Figure 2a) was 
based on the data from Shalaeva et al. (2008), determined by capillary electrophoresis (CE)  
at I = 0.05 M.  The value is predicted to be 9.63 at I = 0.15 M (cf., Sec. 3.1). At 37 oC, the 
n-PrOH/water-extrapolated pKa 9.11 ± 0.03 (Figure 2b) was accordingly lower than the room 
temperature value. 
Chlorpromazine·HCl at 25 oC (Figure 2c) was an extrapolation from high MeOH/water 
ratios, to avoid precipitation and to minimize surface activity effects. Two sources of 
potentiometric (Avdeef, 1994, 2001) and CE (Shalaeva et al., 2008) data were merged in the 
weighted linear regression analysis.  Although the average ionic strength was 0.11 M, the 
measured pKa corrected to I = 0.15 M (Sec. 3.1) remained essentially unchanged. 
Generally, the two-pKa piperazine-containing derivatives were less problematic to 
assess, especially at 37 oC, as illustrated in Figures 2g-2l.  It is interesting that the lower pKa 
value could be determined from cosolvent-free titrations. The direct measurements at zero 
cosolvent validated the extrapolation procedure from n-PrOH/water sets (Figures 2h, j, l). In 
retrospective, it may be that the 25 oC pKa1 (the lower pKa) for trifluoperazine·2HCl (Tsinman et 
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al., 2011) could have been determined in cosolvent-free solution. The MeOH/water psKa1 
values of that molecule indicated progressively higher errors with increasing amounts of 
methanol. This may be due to the decreased solubility of the dicationic salt in the organic 
solvent (Figure 2k).  
It was apparent that the best overall results (gathered in Table 2) were those obtained 
by linear extrapolation of the apparent pKa, psKa, from n-PrOH/water (at 37 oC) and 
MeOH/water (at 25 oC) mixtures (psKa vs.  wt%) to zero cosolvent.  These were better than 
those obtained by the Yasuda-Shedlovsky procedure, following the reasoning detailed 
elsewhere (Avdeef, 2012). The extrapolated values are very close of those obtained in 
aqueous solution by means of D-PAS instrument, where comparisons could be made.  
 
 
 
3.3 Intrinsic solubility and sub-micellar speciation determination 
Table 3 summarizes the results of the solubility-pH data analysis at 25 and 37 oC.  (The units of 
the constants may be simply deduced by taking into account that all concentrations used in the 
analysis are based on molarity.)  Each of the log S-H profiles is illustrated in Figure 3.   
 
3.3.1 Henderson-Hasselbalch relationship 
The dashed curves in Figure 3 were calculated with the Henderson-Hasselbalch (HH) equation, 
using the pKa values from Table 2 and the intrinsic solubility values from Table 3.  In the 
curves, the region for pH >> pKa has zero limiting slope and the region for pH << pKa has a 
limiting slope of -1 (or -2 for pH << pKa1 in the 2-pKa piperazine derivatives). The measured 
log S values (solid circles) can deviate from the HH curves when (a) drug salts precipitate, (b) 
water-soluble aggregates form, (c) solutions remain substantially supersaturated, (d) LLPS oils 
or “drug-rich” particulates (Indulkar et al., 2015) separate, (e) amorphous solids form to differing 
extents as a function of pH, or (f) when the analytical method reaches its limit of detection. 
 
3.3.2 Solution chemistry model construction – “Shape Templates”   
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The solid lines in Figure 3 are best-fit curves through the measured log S values, calculated 
from the mass balance equations corresponding to the refined constants for the proposed 
reactions (below).  A step-by-step solubility model construction (for a case similar to that of 
fluphenazine, Figure 3g) was described recently (Avdeef, 2014a).  Each of the log S-pH profile 
shapes in Figure 3 was compared against a series of templates (Avdeef, 2007, 2012). For 
example, if the apparent slope in the log S-pH profile for pH < pKa is -2 rather than -1 (as 
expected for one-pKa derivatives), then a dicationic dimer, B2H22+, may be indicated (Case 2b: 
Avdeef, 2007). A slope of -3 would suggest the presence of a trimer, and so on. However, if the 
slope is the normal -1, but the log S-pH curve as a whole is shifted to higher pH (appearing to 
indicate a higher pKa than that measured independently), then a “half” charged aggregate, 
(B2H+)n, may be indicated (Case 3b: Butcher et al., 2015). In the study here, numerous species 
were tested against the data, but only dimeric species were needed to rationalize the 
aggregation data region (pH > 6). This templating process requires knowing the accurate pKa, 
independently determined under conditions where precipitation and aggregation are absent 
(Butcher et al., 2015).  
 
3.3.3 Model reactions and constants 
The following reactions proved to be in best agreement with the data (not all for each drug).  As 
a generalized example of a monoprotic weak base, B, a saturated solution can be defined by 
the equations and the corresponding reaction quotients: 
 
BH+         H+ + B     Ka = [H+][B] / [BH+ ]   (1)  
2 BH+            B2H22+     K2B2H2 = [B2H22+] / [BH+ ]2   (2)  
B + BH+       B2H+    K2B2H = [B2H+] / [B][BH+ ]   (3)  
2 B            B2     K2B2 = [B2] / [B]2   (4) 
B(s)     B     S0 = [B]     (5)  
(BH+)2·HPO42-(s)          2 BH+ + HPO42-  Ksp2:1 = [BH+]2 [HPO42- ]  (6) 
BH+·H2PO4-(s)                 BH+ + H2PO4-  Ksp1:1 = [BH+] [H2PO4- ]  (7) 
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The solubility of a drug substance at a particular pH is defined as the mass balance sum of the 
concentrations of all of the species dissolved in the aqueous phase, adjusted for the degree of 
aggregation: 
  
S = [B] + [BH+] + 2 [B2H22+] + 2 [B2H+] + 2 [B2]       
   = [B] + [H+][B] /Ka + 2 K2B2H2 [H+]2[B]2 /Ka2 + 2 K2B2H [H+][B]2/Ka + 2 K2B2 [B]2 (8) 
 
where the square brackets denote molar concentration of species.   
It may be noted that in the full log S-pH profile (consisting of free base and salt 
precipitation), the pH point of discontinuity (e.g., pH 7.8 for promazine, Figure 3a), where the 
drug salt solubility portion of the curve intersects that of the free base, is called pKaGibbs, a term 
introduced by Avdeef (1998), and further elaborated by Streng (1999).  In the literature, this 
point is sometimes called “pHmax”, suggesting that the solubility reaches its maximum value at 
that point. However, the latter term is not general, since it has been shown that the intersection 
point may occur at solubility well below the maximum value, as in the examples of drug 
phosphate salts of verapamil, carvedilol, mifepristone, cyproheptadine, and thioridazine 
(Avdeef, 2014b). 
 Eq. (8) may be further transformed to contain only constants and [H+] (as the only 
variable).  For pH > pKaGibbs, where the free base is the sole precipitate, [B] becomes constant, 
denoted as S0 ( “intrinsic” solubility).  On factoring [B] out of the second line of Eq. (8) and 
expressing the equation in logarithmic form, one gets 
 
log S = log S0 + log ( 1 + [H+]/Ka  + 2 S0 { K2B2H2 [H+]2/Ka2 + K2B2H [H+] /Ka + K2B2 } )        
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If the solubility measurements were carried out in an acidic solution (pH < pKaGibbs), with 
enough compound added that the solubility products [BH+]2 [HPO42- ] and/or [BH+] [H2PO4- ] are 
exceeded, then Eq. (8) would be cast in terms of [BH+] being constant rather than [B], and S0 
being replaced with the solubility product expression(s).   
With the 2-pKa drugs, one would also need to expand Eqs. (1)-(7) accordingly, and 
consider the additional possible solubility products: [BH22+] [H2PO4-]2, [BH22+] [HPO42-], 
[BH22+] [Cl-] [H2PO4-], etc., which would make Eqs. (8) and (9) further complicated.  The low-pH 
(< pKa1) data (if enough compound were added to exceed the above solubility products) could 
be quite complex and challenging to interpret for all the possible diprotic-drug phosphate salt 
formations.  This low pH region was beyond the scope of the present study.  
All such complex equations are sorted out implicitly in the mass action algorithm of 
pDISOL-X, and their explicit derivations are not necessary. 
 
3.3.4 Promazine hydrochloride 
In the free-base precipitation region, the promazine·HCl profile showed near adherence to the 
expected HH shape (Figures 3a, b).  Below pH 7.7, promazine at 25 and 37 oC showed signs of 
2:1 drug phosphate precipitation.  To describe such processes, Eq. (6) needs to be considered.  
In the 2:1 salt solubility region where pH < pKaGibbs, Eq. (8) still holds, but [BH+] becomes 
constant, instead of [B]. Eq. (9) can be modified to reflect this, as described in detail elsewhere 
(Avdeef, 2012; Völgyi et al., 2013).   
 
3.3.5 Chlorpromazine hydrochloride 
Chlorpromazine·HCl is the most insoluble derivative considered here. Below pH 8, there is 
deviation from the HH form, consistent with the formation of dicationic dimers (Figure 3c,d).  
The three points at the lowest pH at 25 oC may indicate some supersaturation (Serajuddin and 
Rosoff, 1984; Serajuddin and Jarowski, 1985).  It is noteworthy that the sub-micellar 
aggregates compete with the formation of phosphate salts. Concentrations of chlorpromazine 
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at 37 oC (Figures 3d) would need to be greater than 1 M before drug-phosphate salts would be 
expected to precipitate, due to the presence of stable B2H22+ dimers depleting the BH+ species 
needed in the precipitate.  There is substantial uncertainty in this prediction, due to the 
presence of the charged dimers. 
 
3.3.6 Triflupromazine hydrochloride 
As with chlorpromazine·HCl, triflupromazine·HCl may indicate some supersaturation below  
pH 7 at 25 oC (Figure 3e). As a departure from HH form, the most prominent feature in  
the log S-pH profile at 25 oC is the levelling off of points above pH 9, which may indicate  
the formation of  water-soluble uncharged Bn aggregates (Case 1b: Avdeef, 2007). The value of 
n cannot be determined from pH dependence; n = 2 (cf., Eq. 4) was used for the refined 
constant (Table 3). Alternative explanations for the effect above pH 9 may be that (a) the 
solutions still remained supersaturated at the end of 24 h incubation time, or (b)  partial LLPS 
oil separation persisted at the end of 24 h, or (c) the solid was amorphous preferentially in 
alkaline suspensions at the end of 24 h, or (d) simply that the analytical method reached its 
limit of detection. Nine compounds out of 25 bases were found (Avdeef, 2014b) to show this 
effect in the study of Bergström et al. (2004).  Additional investigation is needed to better 
understand the nature of the non-HH behavior in basic solution. 
 
3.3.7 Fluphenazine dihydrochloride 
Fluphenazine·2HCl at 25 oC departed from HH form (Figure 3g), with a half-charged aggregate, 
(B2H+)n, indicated (Case 3b: Butcher et al., 2015). It is not possible to determine the 
aggregation number from pH dependence alone, so n=1 (i.e., species B2H+) was selected in 
the refinement of the dimer constant. The effect is less prominent at the higher temperature 
(Table 3). 
It is noteworthy that the stable half-charged aggregate at 25 oC is expected to compete 
with the formation of phosphate salts by diminishing the formation of the BH+ species, thus 
raising the predicted salt solubility (see below) to about 240 mg·mL-1 below pH 5 (Figure 3g).  
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Experimental data below pH 7 are needed to further understand this largely uncharted Case 3b 
phenomenon, as the predictions are expected to be substantially uncertain there. 
Lower salt solubility is predicted at 37 oC, compared to 25 oC, since the half-charged 
aggregate is weaker. The predicted (cf., Sec. 3.3.10) step discontinuity near pH 5.6 in 
Figure 3h marks the transition across the pKaGibbs.  At pH 5.1, the solid is predicted to be 
BH·H2PO4(s).  However, at pH 5.5, two solids are predicted to co-precipitate: BH·H2PO4(s) and 
(BH)2·HPO4(s) at the salt pKaGibbs.  Above pH 5.6, only the B(s) solid is present in the saturated 
solution.  
 
3.3.8 Perphenazine 
Perphenazine (Figures 3i,j), the only phenothiazine introduced as a free base, appears to show 
only a small amount of aggregation.  At 25 oC, Case 1b and 2b aggregates best rationalize the 
data.  At 37 oC, the best fit of the data is with a Case 3b aggregate.    
 
3.3.9 Trifluoperazine dihydrochloride 
Trifluoperazine·2HCl shows substantial aggregation at both temperatures (Figure 3k,l).  When 
drug phosphate salts are included in the model (see below), all solid is predicted to dissolve 
below pH 5 up to about 1 M added compound.  The presence of the dicationic dimers is 
predicted to elevate salt solubility above 240 mg·mL-1.  The levelling off of data at 25 oC for 
pH > 8 may have similar interpretations as that of triflupromazine at 25 oC.  
 
3.3.10 Prediction of phosphate salt solubility products 
The pDISOL-X analysis of twenty-five low-soluble one-pKa bases (Avdeef, 2014b), using 
log S-pH measurements in 0.15 M phosphate buffer (Bergström et al., 2004), revealed 
correlations between the intrinsic solubility and the two phosphate solubility products: 
 
log Ksp2:1 = -0.76  +1.20 log S0     (10) 
log Ksp1:1 = -0.53  +0.55 log S0     (11)  
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These novel solubility product prediction equations were applied to the phenothiazines 
(cf., Table 3).  The dash-dot curves in Figure 3 are based on the predictions.  The agreement 
between prediction and measurement was good for promazine·HCl at both temperatures, and 
fair in the case of triflupromazine at 37 oC.   
Eqs. (10) and (11) could be useful in planning experimental conditions for future studies 
dedicated to characterizing the phosphate solubility products of the drugs.  They are used here 
mainly as guides of what to expect for pH < 6 profiles, where drug-phosphate salts are 
expected to form.  Eqs. (10) and (11) would not apply to the 2-pKa molecules in the low-pH 
(< pKa1) regions, as noted earlier. 
 
3.4 Phenothiazine thermodynamics  
The differential scanning calorimetry (DSC) thermograms in Figure 4 confirm the polymorphic 
homogeneity of most of the solid samples.  The dotted curves correspond to the starting forms 
of the solids used (mostly mono- or dihydrochloride, with one free base).  The dashed curves 
correspond to solids isolated from solutions near pH 7, at the 24 h time points.  The solid curves 
refer to those of the substances isolated near pH 10 at 24 h.  
The DSC was used to determine the melting points and enthalpies of fusion (mostly of 
chloride salts), as summarized in Table 4.  Only fluphenazine·2HCl indicated a solid-solid 
phase transition temperature (215.8 oC / 488.9 K). Perphenazine, being a free base, showed 
the lowest melting point (96.8 oC / 370.0 K) of the compounds studied.  The melting enthalpy 
values range from 35.0 kJ·mol−1 (promazine·HCl) to 64.5 kJ· mol-1 (triflupromazine·HCl), and 
are typical values for organic compounds. The highest value of the enthalpy of melting 
(triflupromazine HCl) was concomitant to the decomposition of the substance. 
    The determination of log S0 at two temperatures allowed for the calculation of the 
enthalpy of solution, using the van’t Hoff equation,  



 
12
0
12
11
303.2
loglog
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where R = 8.3143 J·mol-1,  T1 = 298.15, and T2 = 310.15 K.  The calculated values (Table 4) 
are all positive, indicative of an endothermic dissolution process.  The three least soluble drugs 
have the highest heats of dissolution: ∆Hsol0 = 152, 134, 99 kJ·mol-1 for chlorpromazine, 
triflupromazine, and trifluoperazine, respectively.  The last column in Table 4 lists the predicted 
values of enthalpy of solution, based on a multiple linear regression model, trained with 626 
molecules (Avdeef, 2015b).  It is interesting to note that the above three least-soluble 
phenothiazines have the highest discrepancies between measured and calculated enthalpies.  
On the other hand, the agreement between the calculated and measured enthalpies of solution 
for the three most-soluble molecules is within the experimental uncertainties in such 
measurements (Avdeef, 2014b).  It may be that the sub-micellar aggregation with the least-
soluble molecules has an impact on the heats of dissolution based on the two-temperature 
results reported here. This is consistent with observations of others, that the solubility of drugs 
prone to the forming aggregates can be strongly dependent on temperature (Bogardus and 
Blackwood, 1979).     
 
3.5 Solid form isolated from suspensions 
The melting points reported in the literature for free-base phenothiazine derivatives are low: 
25 oC for trifluoperazine and triflupromazine, 33 oC for promazine, 57 oC for chlorpromazine, 
and 96.8 oC for perphenazine (Bradley et al., 2016).  At the 24 h incubation time point, the 
solids isolated from the suspensions in this study did not appear to be oils by visual inspection.  
However, the calorimetric data were not straight forward to interpret.  The DSC of solids 
separated from suspensions near pH 7 (dashed curves in Fig. 4) were largely featureless, 
possibly suggesting the presence of amorphous solids.  This was the pH region where the solid 
was expected to be the free base form.  The neutral pH region may be prone to 
supersaturation, more so than the pH 10 region.  It was surprising that the drug substance 
isolated from pH 10 suspensions (solid curves in Fig. 4) showed sharp negative peaks in the 
DSC, corresponding to the starting salt forms of the solids (with the exception of 
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perphenazine), persistently 1-2 oC lower than those of the starting material (dotted curves in 
Fig. 4).  The reasonable explanation for this is as follows.  When the excess salt forms of the 
drugs were added to the buffer solutions at the low-pH end of the range selected and the pH 
values were adjusted with 0.1M KOH, the surfaces of the solids became covered with the free 
base which forms.  (In the 37 oC solubility experiments, the free base may have been oil for 
some of the derivatives.)  The encased drug chloride salts apparently become insulated from 
the aqueous phase.  The free-base coating established an apparent equilibrium with the 
aqueous phase.  This happens in rotating-disk dissolution studies, where hydrochloride salts of 
weak-base drugs dissolve quickly but then re-precipitate in the pH 6.8 phosphate buffer media 
as free bases on the surface of the dissolving rotating drug salt pellet (e.g., as shown visually 
for papaverine in Fig. 4 in Avdeef and Tsinman, 2008).  This would not happen with 
perphenazine, since it had been introduced as a free base (cf., Fig. 4e), given that the 
observed melting point is identical to the literature value for the free base.  If the coating on the 
surface of incompletely dissolved salt particles were the free base in crystalline form, then a 
DSC scan at low temperature might have partially revealed the expected low melting points.  
However, the DSC scan from 0 – 220 oC for promazine isolated from pH 10 suspension 
(Fig. 4a) shows a featureless plot near the expected 25 oC melting point region.  The tentative 
conclusion is that the solid materials in our solubility studies were largely if not entirely 
amorphous, with the exception of perphenazine.  Clearly, the solid state characterization is not 
complete and will require further detailed study, at longer incubation times than the 24 h in 
present study. 
 The “salt particles coated with free base” effect can be easily eliminated by (a) selecting 
a lower pH buffer (pH < 6) into which the salt is initially added, and (b) by using a smaller 
excess of salt to add to the buffer.  Once the salt completely dissolves, additions of NaOH can 
commence to elevate the pH so free-base precipitates can form (free of entrapped salt). This 
was demonstrated with chlorpromazine hydrochloride, where the recovered solid base from the 
pH 10 solution showed the expected 57 oC melting point by DSC (data not shown).  
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3.6 Solid form introduced can influence supersaturation at pH near the pKaGibbs 
Zografi and Zarenda (1966) noted that chlorpromazine added to distilled water as the 
hydrochloride salt showed surface activity, but not when introduced as the free base. This 
could be due to the starting pH of the saturated water solutions.  Since perphenazine was the 
only drug introduced as the free base in the present study, and since it showed a lesser 
tendency to form aggregates, compare to the other derivatives, it is useful to take note of the 
impact of the solid form introduced to solution on the presence/persistence of aggregates.  
Serajuddin and Mufson (1985) determined the log S-pH profiles of tiaramide at 1-2 h time 
points by introducing the free base or the hydrochloride form of compound.  The pH region near 
the pKaGibbs showed a strong tendency for supersaturation, regardless of the initial solid form of 
the drug.  The same was so of the apparent cationic tetramer of tiaramide formed in the pH 4-5 
interval.  It was not reported how long the apparent aggregate persisted, since the system at 
1-2 h may not have reached a steady state. Other drugs, studied over longer times, showed a 
similar tendency to supersaturate near the pKaGibbs region of pH, often accompanied by the 
formation of aggregates on the free-base/acid side of the profile (Serajuddin and Rosoff, 1984; 
Serajuddin and Jarowski, 1985; Ledwidge and Corrigan, 1998; Li et al. 2005a, b).  As far as we 
are aware, there have not been reported studies of the stability of the sub-micellar aggregates, 
although it is thought that supersaturation is time dependent.   
 
3.7 Implications of sub-micellar aggregation 
The last column in Table 3 lists the literature values of the phenothiazine CMC in acidic (pH 2) 
and phosphate-buffered (pH 6.9) solutions.  The reported CMC of trifluoperazine and 
chlorpromazine in the pH 6.9 phosphate buffer at 25 oC are 37 and 150 μM, respectively.  The 
log S-pH profiles of chlorpromazine and trifluoperazine (Figures 3c,k) indicate a sub-micellar 
aggregates at concentrations above the reported CMC (Zografi et al., 1964).   
Ottaviani et al. (2015) considered the practical importance of CMC values of drugs.  
They found that in biorelevant media (e.g., bile salts), CMC values better correlated with the 
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solubility enhancement effect than did traditional lipophilicity descriptors (i.e., octanol-water 
partition coefficients).  More complete knowledge of the sub-micellar aggregation property of 
candidate molecules could impact on formulation decisions, e.g., based on biorelevant media 
studies, and in the design and interpretation of salt selection investigations (Casares et al., 
2015). 
 
3.8 Comparison of intrinsic solubility to literature values 
A thorough search of the literature revealed multiple sources of intrinsic solubility values for all 
of the phenothiazines studied here.  Almost all values were reported near room temperature 
(20-25 oC), with the exception of fluphenazine, which was only available at 37 oC.  Table 5 
summarizes the comparisons and Figure 5 displays the correlation between the values 
reported here and the averaged values from the literature.  Before averaging the room 
temperature results, all room temperature values were transformed to a common 25 oC basis 
using a recently described procedure (Avdeef, 2015b), to match the temperature in the study 
here. 
 Figure 5 shows nearly perfect agreement for fluphenazine, promazine, and 
triflupromazine.  For the other three compounds, the values reported here are up to 0.5 log 
units lower than the average values reported in the literature.  This is an important observation.   
 Since our solid state characterization suggested the possibility of amorphous character 
to the solids isolated at the end of 24 h incubation times, it was of interest to estimate how far 
we may have been from the crystalline solid state (as a measure of equilibration).  We selected 
24 h as the incubation time based on constancy of concentrations rather than the presence of 
crystalline solids.  It is noteworthy that in some of the literature methods (Table 5) incubation 
times of 24, 48, and 72 h were employed.  It is frequently suggested that solubility values of 
amorphous solids are expected to be higher than that of crystalline solids.  If our results were 
typical of amorphous solids, then all of the points in Figure 5 should have been above the 
identity line.  That is not what is indicated in Figure 5.  We thus propose that our reported 
values at the end of 24 h incubation are indistinct from those expected of values at true 
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chemical equilibrium. 
 
4. Conclusions 
For the six phenothiazines studied here, it was possible to rationalize the complex log S-pH 
profiles measured in 0.15 M phosphate buffer at 25 and 37 oC in the pH 6-11 region.  This was 
so because highly reliable pKa values became available, determined independently of the 
solubility data, under optimized conditions designed to avoid precipitation and sub-micellar 
aggregation.  A state-of-the-art mass action computational algorithm was used to interpret the 
solubility data.  Positively-charged sub-micellar aggregates were evident for chlorpromazine, 
fluphenazine, perphenazine, and trifluoperazine at 25 oC.  The effects persisted at 37 oC for 
chlorpromazine and trifluoperazine.  The presence of such aggregates may have been 
anticipated by the known surface-active behavior of the phenothiazines (e.g., very low CMC 
values in buffered solutions). The solution model developed here could be applied to fine-tune 
salt selection procedures of surface active molecules, and is expected to be useful in predicting 
to what extent solubility enhancement may be achieved by using biorelevant media.  The DSC 
characterization suggested the presence of some amorphous form of solid in suspensions at 
the 24 h incubation time in cases where the drug was introduced as a chloride salt.  
Perphenazine, introduced as a free base, appeared to be crystalline when isolated from 
alkaline solution.  Based on the comparison between the intrinsic solubility values reported 
here and the twenty-two values taken from the literature, we conclude that the 24 h incubation 
reached a state that may be indistinguishable from thermodynamic equilibration, within the 
bounds of experimental error, even though some of our solid state characterizations suggested 
the presence of amorphous solids.  This will be further investigated in future studies by using 
solely free base phenothiazines as starting forms of solids.  
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Table 1 - Conditions during chromatographic separation a 
Compound A(%) B(%)
Flow Rate 
(mL·min-1) λ(nm) 
Promazine.HCl 70 30 1 245 
Chlorpromazine.HCl 70 30 1 255 
Triflupromazine.HCl 75 25 1 250 
Perphenazine 70 30 1 255 
Fluphenazine.2HCl 65 35 1 255 
Trifluoperazine.2HCl 75 25 1 255 
a Mobile phases: A = methanol, B = pH 7 phosphate buffer. 
 
  
Table 2 - Ionization constants (pKa) of phenothiazine derivatives at 25 and 37 oC a
Compound pKa t (
oC)
Ionic 
Str. (M) Cosolvent Range
Weighted 
Fit Slope a Ref
Promazine.HCl 9.63 ± 0.10 b 25 0.15 b 30-60 wt% MeOH -0.0205 Shalaeva et al. , 2008
9.11 ± 0.03 37 0.16 15-33 wt% n-PrOH -0.0486 this work
Chlorpromazine.HCl 9.57 ± 0.02 c 25 0.15 g 30-60 wt% MeOH -0.0240 Avdeef, 1994, 2001; Shalaeva et al ., 2008
8.70 ± 0.03 37 0.16 15-33 wt% n-PrOH -0.0413 this work
Triflupromazine.HCl 9.47 ± 0.01 d 25 0.15 5-64 wt% MeOH d -0.0246 this work
8.65 ± 0.02 37 0.16 15-33 wt% n-PrOH -0.0438 this work
Fluphenazine.2HCl 7.84 ± 0.02 e 25 0.18 20-39 wt% MeOH -0.0094 Tsinman et al ., 2011
3.98 ± 0.03  e 25 0.18 20-39 wt% MeOH -0.0157 Tsinman et al. , 2011
7.51 ± 0.03 37 0.16 15-33 wt% n-PrOH -0.0274 this work
3.37 ± 0.04 37 0.16 0-33 wt% n-PrOH -0.0293 this work
Perphenazine 7.95 ± 0.04 25 0.19 12-39 wt% MeOH -0.0085 Tsinman et al ., 2011
3.66 ± 0.10 25 0.19 12-39 wt% MeOH -0.0235 Tsinman et al ., 2011
7.64 ± 0.02 37 0.16 15-33 wt% n-PrOH -0.0303 this work
3.42± 0.04 37 0.16 0-33 wt% n-PrOH -0.0214 this work
Trifluoperazine.2HCl 8.43 ± 0.17 25 0.17 26-48 wt% MeOH -0.0167 Tsinman et al ., 2011
4.85 ± 0.85  f 25 0.17 26-48 wt% MeOH -0.0603 Tsinman et al ., 2011
7.92 ± 0.06 37 0.15 15-33 wt% n-PrOH -0.0332 this work
3.70 ± 0.03 37 0.15 0-33 wt% n-PrOH -0.0387 this work
a The individual apparent pK a  values as a function of % cosolvent were extrapolated to zero cosolvent, using weighted linear regression.
   Cosolvent potentiometric data were used, except as noted.
b Cosolvent capillary electrophoresis data (I = 0.05 M), with extrapolated pKa = 9.62. Value was then adjusted to I  = 0.15 M basis.
c Combined cosolvent potentiometric (I = 0.16 M) and capillary electrophoresis data (I = 0.05 M).  Final pK a  is reported with reference to I  = 0.15 M.
d Combined cosolvent potentiometric (34-64 wt% MeOH) and spectrophotometric (5-52 wt% MeOH) data.
e With the 2-pK a  piperazine derivatives, the higher value refers to pK a2  and the lower  value (italic) refers to pK a1 .
f The high error may be indicative of precipitation of the doubly-charged drug in methanol-rich solutions.
g The actual average ionic strength in the combined CE and potentiometric data was I = 0.11 M. The pK a was essentially unchanged at I = 0.15 M. 
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FIGURE CAPTIONS 
Fig. 1 - Chemical structures of the six phenothiazine derivatives.  
Fig. 2 – Weighted linear regression plots, psKa vs. wt% cosolvent, of the phenothiazine 
derivatives at 25 oC (MeOH/H2O) and 37 oC (n-PrOH/H2O).  Most of the data are based 
on potentiometric determinations, with the following exceptions.  The promazine plot at 
25 oC (Fig. 2a) is based on CE data (Shalaeva et al., 2008). For chlorpromazine at 
25 oC (Fig. 2c), the square symbols denote CE determinations (Shalaeva et al., 2008), 
whereas the circles correspond to potentiometric data (Avdeef, 1994, 2001). For 
triflupromazine at 25 oC (Fig. 2e), the unfilled circles are based on spectrophotometric 
data, while the filled circles are from potentiometric determinations.  Table 2 
summarizes the results of the pKa analysis.  
Fig. 3 – Solubility-pH profiles for the phenothiazine derivatives at 25 and 37 oC, adjusted to the 
reference ionic strengths 0.15-0.19 M, the mean values from the pKa determinations 
(see text). The dashed curves were calculated with the Henderson-Hasselbalch 
equation, using the pKa and S0 constants (Tables 2 and 3).  The solid lines are best-fit 
refinement curves through the measured log S-pH points. The dash-dot curves below 
pH 7 were calculated from the predicted solubility products, using Eqs. (10) and (11).  
There was evidence of precipitation of the 2:1 drug-phosphate salt for promazine (both 
temperatures) and triflupromazine (37 oC). The dotted lines (Figs. 3k,l) indicate that the 
compound is predicted to completely dissolve even in 1 M solutions (see text). The 
black-circle-with-cross-at-the-center symbols in the 2-pKa drug plots (g-l) indicate the 
pH points corresponding to the two pKa values.  The details of the calculations are 
summarized in Table 3. 
Fig. 4 - Differential scanning calorimetry (DSC) thermograms of the phenothiazine derivatives, 
taken of the original solids (dotted curves), the solids isolated from pH 7 suspensions 
(dashed curves) and pH 10 suspensions (solid curves). 
Fig. 5 – Comparison of intrinsic solubility of phenothiazines to averaged values taken from the 
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literature.  The literature results are summarized in Table 5 and are at 25 oC (except 
fluphenazine, which is at 37 oC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 – Pobudkowska et al. 
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Fig. 2 – Pobudkowska et al. 
 
 
 
Fig. 2 – Pobudkowska et al. 
  
 
Fig. 3 – Pobudkowska et al. 
 
 
Fig. 3 – Pobudkowska et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 – Pobudkowska et al. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 – Pobudkowska et al. 
 
